Two different entry points to the same axis: receptor assays and rat models for ipamorelin, GHRH analogue chemistry for tesamorelin. Research use only.
What the compounds are
Ipamorelin is a synthetic pentapeptide amide with the structure Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C38H49N9O5, molecular weight 711.90 g/mol, CAS number 170851-70-4. Three of its five positions are non-standard: alpha-aminoisobutyric acid at the first position and D-configured aromatic residues at the third and fourth, with a C-terminal amide. Those substitutions are what distinguish it chemically from a natural peptide sequence and what the original characterisation work set out to describe (PMID 9849822).
Tesamorelin is a 44-residue analogue of growth hormone releasing hormone, GHRH(1-44), carrying an N-terminal trans-3-hexenoyl group, molecular formula C221H366N72O67S, molecular weight 5136.00 g/mol, CAS number 218949-48-5. It is an order of magnitude larger than ipamorelin and belongs to a different chemical class: a modified full-length releasing hormone rather than a small synthetic secretagogue. All compounds discussed are supplied strictly as laboratory research materials. They are not for human or veterinary use, and nothing here is medical advice.
The research question
Both materials are studied in relation to the same physiological axis but through different receptors, and the literature reflects that split. The ipamorelin corpus is receptor pharmacology and rodent work: binding and activation at the growth hormone secretagogue receptor measured in cell systems, hormone release measured in cultured pituitary cells, and growth or exposure measured in rats. The tesamorelin corpus is analogue chemistry and clinical development, which places most of it outside what a research-materials catalogue can usefully summarise.
The endpoints in the preclinical studies below are laboratory endpoints: receptor occupancy and activation in a defined expression system, hormone concentration in culture supernatant or in animal plasma, bone length measured in rats, and plasma concentration over time in animal pharmacokinetic experiments. No human outcome is described in this article.
Receptor pharmacology and binding-domain studies
The receptor is the growth hormone secretagogue receptor, and two of the cited papers deal with it directly. A structural and mutational study characterised the binding domain of the receptor, mapping which regions of the receptor protein are involved in ligand interaction using expression-system assays (PMID 35959447). Work of this kind is done in transfected cells rather than in tissue, and its measured variables are binding and activation parameters for defined receptor constructs.
A companion review sets out the receptor family and the range of ligands described for its members, which is the context needed to read any single secretagogue result correctly (PMID 11322507). Selectivity claims in this field are claims about a panel of receptors tested in parallel, and the review is the map of that panel. Ipamorelin was introduced in the literature specifically as a selective secretagogue, and selectivity in that original report is a statement about which receptors were tested and which responded (PMID 9849822).
Two caveats attach to receptor work of this kind. Expression systems present the receptor at densities and in cellular contexts that differ from the tissues where it occurs naturally, so binding and activation parameters measured there describe the construct and the assay as much as the receptor. And selectivity is only ever demonstrated against the panel that was actually tested, which means a selectivity statement from 1998 is bounded by the receptors known and screened at that time.
Pituitary cell and somatotroph models
The cell-level model in this field is the cultured pituitary cell preparation, in which somatotrophs are held in culture and hormone released into the medium is measured by immunoassay. The original characterisation of ipamorelin used in vitro pituitary systems alongside animal experiments to establish the release profile and the selectivity panel (PMID 9849822).
A later rat study took a different design: young female rats were treated chronically, then the somatotroph response was assessed in vitro on cells taken from those animals (PMID 12168778). That combination, chronic exposure in the animal followed by an ex vivo cellular measurement, answers a question the acute culture assay cannot, namely whether the cellular response measured in the dish differs after prolonged exposure in the intact rat. The measured variables are cellular and immunohistochemical rather than whole-animal.
Rat growth and pharmacokinetic models
The clearest whole-animal endpoint in the ipamorelin literature is skeletal. In a rat model, longitudinal bone growth was the measured variable, assessed as bone length in treated animals against controls (PMID 10373343). Bone length is attractive experimentally because it is an unambiguous physical measurement that integrates exposure over the treatment window rather than sampling a single time point.
Exposure itself was addressed in a pharmacokinetic evaluation that compared ipamorelin with other peptidyl secretagogues in animal experiments and gave particular attention to absorption across the nasal mucosa (PMID 9879640). Comparative pharmacokinetics of this type is a laboratory characterisation exercise: the variables are plasma concentration over time and derived exposure parameters in the animal model used, and the comparison is between molecules rather than between conditions.
The two rodent designs complement each other. A bone-length measurement integrates the whole treatment window in the intact rat but says nothing about which cells changed, while an ex vivo somatotroph assessment identifies the responding cell population but is taken from animals removed from the experiment. Neither alone establishes a chain from receptor to tissue, and the cited rat studies do not attempt to close that chain.
Tesamorelin and the GHRH analogue literature
The available review of tesamorelin describes it as a human growth hormone releasing factor analogue and covers its development as an investigational agent (PMID 19243281). What can be taken from it in this context is chemical and pharmacological framing: tesamorelin acts at the GHRH receptor rather than at the secretagogue receptor, and the N-terminal hexenoyl modification was introduced to alter the stability of the native releasing hormone sequence.
Clinical literature exists for tesamorelin in HIV-associated lipodystrophy, and it is outside the scope of a research-materials catalogue. No clinical result is summarised here. For a laboratory, the practical consequence of the receptor difference is that ipamorelin and tesamorelin are not interchangeable comparators: an experiment at the secretagogue receptor does not report on the GHRH receptor, and a design that treats the two as one axis loses the distinction that makes each of them useful.
Limits of the evidence
The ipamorelin preclinical corpus is old, small and largely traceable to the original development programme, with rats and cultured pituitary cells as the subjects. Receptor studies are performed in expression systems, which measure receptor behaviour rather than tissue behaviour. The tesamorelin material available here is a review rather than a primary preclinical study, so this article says less about it by design.
Across both, the measurements are animal and cell measurements. They do not extrapolate to people, no administration or protocol guidance appears anywhere in this article, and none should be inferred from the model descriptions above.
There is also an asymmetry of evidence between the two materials that should not be smoothed over. The ipamorelin literature cited here is primary preclinical work with named cell and rodent models. The tesamorelin material cited here is a single review, and its subject matter sits largely in clinical development, which this catalogue does not summarise. An article that presented the two as equally characterised at the preclinical bench would misdescribe the sources it rests on.
Related materials in the catalogue
Product pages are ipamorelin and tesamorelin, with compound guides at the ipamorelin research guide and the tesamorelin research guide. Both are listed in the cellular category. A side-by-side treatment of the two is available in the ipamorelin and tesamorelin comparison, and mitochondrial metabolic work on a different material is covered in the MOTS-c article.
Analytical documentation for each lot is published under certificates, the reconstitution calculator handles solvent volumes, and the analytical background is set out in how to verify a peptide certificate of analysis, HPLC peptide purity, mass spectrometry peptide testing and what a 99 percent purity figure means. All compounds discussed are supplied strictly as laboratory research materials. They are not for human or veterinary use, and nothing here is medical advice.
References
- Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 1998. PMID 9849822
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 1999. PMID 10373343
- Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica; the fate of foreign compounds in biological systems, 1998. PMID 9879640
- Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002. PMID 12168778
- Binding Domain Characterization of Growth Hormone Secretagogue Receptor. Journal of translational internal medicine, 2022. PMID 35959447
- Growth hormone secretagogue receptor family members and ligands. Endocrine, 2001. PMID 11322507
- Tesamorelin, a human growth hormone releasing factor analogue. Expert opinion on investigational drugs, 2009. PMID 19243281
Research use only